SCHEMBL6325862

SCHEMBL6325862

CCCCCN(CCS)S(=O)(=O)c1ccc(OC)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMP1 P13497 6/20 0.63
CNR2 P34972 1/20 0.60
MMP13 P45452 4/20 0.52
MMP8 P22894 2/20 0.52
TAS2R14 Q9NYV8 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 1/20 0.49
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49
RAB9A P51151 1/20 0.49
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
MMP2 P08253 1/20 0.48
MMP9 P14780 1/20 0.48
CA9 Q16790 1/20 0.48
MMP1 P03956 2/20 0.48
MMP7 P09237 1/20 0.48
MMP12 P39900 1/20 0.48
MMP3 P08254 1/20 0.47
MEP1B Q16820 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13979922 0.88 CNR2 (0.61) BMP1CNR2MMP13MMP8TAS2R14
SCHEMBL6324195 0.87 SMN1; SMN2 (0.65) BMP1CNR2MMP13MMP8TAS2R14
SCHEMBL14229338 0.85 TAS2R14 (0.62) BMP1CNR2MMP13MMP8TAS2R14
SCHEMBL8183270 0.81 KEAP1 (0.63) BMP1CNR2MMP13MMP8TAS2R14
SCHEMBL14200203 0.80 CNR2 (0.53) BMP1CNR2MMP13MMP8TAS2R14
SCHEMBL6323499 0.78 MMP13 (0.52) BMP1CNR2MMP13MMP8TAS2R14
SCHEMBL8177194 0.78 MMP1 (0.76) BMP1CNR2MMP13MMP8CA1
SCHEMBL8175150 0.78 MMP1 (0.76) BMP1CNR2MMP13MMP8CA1
SCHEMBL6418955 0.78 MMP1 (0.76) BMP1CNR2MMP13MMP8CA1
SCHEMBL4936946 0.77 SMN1; SMN2 (0.77) BMP1MMP13MMP8TAS2R14SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed
EP-0939629-A4 THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS MONSANTO CO (US) 2002-07-17 EP disclosed
EP-0939629-A1 THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS MONSANTO COMPANY (US) 1999-09-08 EP disclosed
WO-1998003166-A1 THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS MONSANTO COMPANY (US) 1998-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 BMP1 2254/4885CNR2 4079/4885MMP13 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.